{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T12:19:12Z","timestamp":1789820352311,"version":"4.0.1"},"reference-count":11,"publisher":"S. Karger AG","issue":"3-4","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology"],"published-print":{"date-parts":[[2011]]},"abstract":"<i>Background\/Aims:<\/i> We measured the extracellular concentrations of fluconazole in lung tissue of septic and healthy rats. <i>Methods:<\/i> A single intravenous dose of 6 mg\/kg total body weight of fluconazole was administered intravenously to rats following insertion of microdialysis probes into lung tissue. Another probe was inserted into skeletal muscle and served as control. <i>Results:<\/i> The mean peak concentration (C<sub>max<\/sub>), time to C<sub>max<\/sub>, area under the concentration-versus-time curve from 0 to 6 h (fAUC<sub>0\u20136<\/sub>) and area under the concentration-versus-time curve from 0 to \u221e of unbound fluconazole for healthy lung were 11.0 \u00b1 2.3 mg\/l, 1.9 \u00b1 1.5 h, 47.4 \u00b1 8.6 mg\u00b7h\/l and 233.7 \u00b1 121.1 mg\u00b7h\/l, respectively. The corresponding values for inflamed lung were 11.8 \u00b1 1.7 mg\/l, 1.5 \u00b1 0.0 h, 52.9 \u00b1 6.2 mg\u00b7h\/l and 212.6 \u00b1 79.7 mg\u00b7h\/l, respectively. The mean apparent terminal elimination half-lives of fluconazole ranged from 12.3 to 22.4 h between compartments. The ratios of the fAUC<sub>0\u20136<\/sub> for lung to the fAUC<sub>0\u20136<\/sub> for plasma were 1.38 \u00b1 0.39 and 1.32 \u00b1 0.04 for healthy and inflamed lung, respectively. <i>Conclusion:<\/i> We provide evidence that free fluconazole levels in plasma, the extracellular space fluid of lung tissue and skeletal muscle are almost superimposable during inflammatory and normal conditions.<\/jats:p>","DOI":"10.1159\/000323738","type":"journal-article","created":{"date-parts":[[2011,2,10]],"date-time":"2011-02-10T07:57:26Z","timestamp":1297324646000},"page":"130-134","source":"Crossref","is-referenced-by-count":8,"title":["The Ability of Fluconazole to Penetrate into Ventilated, Healthy and Inflamed Lung Tissue in a Model of Severe Sepsis in Rats"],"prefix":"10.1159","volume":"87","author":[{"given":"Oliver","family":"Mauric","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Thallinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia A.","family":"Kugler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir M.","family":"Joukhadar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian M.","family":"Kovar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl H.","family":"Konz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Graninger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Joukhadar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2011,2,10]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097%2F00003246-200102000-00030"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1128%2FAAC.48.6.2228-2232.2004"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1128%2FAAC.00885-08"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1128%2FAAC.50.4.1372-1375.2006"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2165%2F00003088-200544090-00002"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1128%2FAAC.49.2.650-655.2005"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093%2Fjac%2F42.1.121"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093%2Fjac%2Fdkq109"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1128%2FAAC.44.9.2569-2571.2000"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093%2Fjac%2Fdkp464"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1365-2125.2010.03656.x"}],"container-title":["Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/323738","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/323738","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T19:24:26Z","timestamp":1745436266000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000323738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":11,"journal-issue":{"issue":"3-4","published-online":{"date-parts":[[2011,4,1]]},"published-print":{"date-parts":[[2011,4,20]]}},"URL":"https:\/\/doi.org\/10.1159\/000323738","archive":["Portico"],"relation":{},"ISSN":["0031-7012","1423-0313"],"issn-type":[{"value":"0031-7012","type":"print"},{"value":"1423-0313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011]]}}}